← All trials
NCT06172010
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2023
- Primary completion
- Mar 31, 2027
- Completion date
- Mar 31, 2028
- First posted
- Dec 15, 2023
- Last posted
- Dec 15, 2023
- Enrollment
- 316
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Leiden UniversityLead sponsor
- Onze Lieve Vrouw HospitalCollaborator
- Radboud UniversityCollaborator
- Rijnstate HospitalCollaborator
- University of GroningenCollaborator
- University of GroningenCollaborator
- Leiden UniversityReponsible party - principal investigator
- Leiden UniversityStudy director
- University of AmsterdamCollaborator
- Isala Clinics, Zwolle, The NetherlandsCollaborator
- Erasmus University RotterdamCollaborator
- Tergooi HospitalCollaborator
- Spaarne GasthuisCollaborator
- Alrijne HospitalCollaborator
- Elisabeth-TweeSteden ZiekenhuisCollaborator
- Reade Rheumatology Research InstituteCollaborator
- Medical Center LeeuwardenCollaborator
- Reinier Haga Orthopedisch CentrumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.